Comparison of presenting symptoms and characteristics of Benign and Malignant Ovarian Tumors
Article Sidebar
Main Article Content
Abstract
Background: Ovarian cancer was over 200,000 new diagnoses each year worldwide.It has the worst prognosis of all gynecological cancers, with an overall five year survival of about 35%. In early cancers ( FIGO Stage I or II ) survival is 80-90 % compared with 25% in late cancer (FIGO Stage III and IV). Currently only 30% of patients are diagnosed in these early stages. No effective screening exists, so that prospect for earlier diagnosis of ovarian cancer.
Objective: To compare presenting symptoms and characteristics of benign and malignant ovarian tumors.
Material and Method: A retrospective descriptive study was conducted. Medical records were reviewed all cases of ovarian tumors operated in Surin hospital during October 2008 to September 2010.
Results: Among 199 patients, 35 patients were diagnosed malignant ovarian tumor. The patients above 50 years were significantly related with malignant tumor. Abdominal mass, abdominal distension and abnormal vaginal bleeding were common symptoms in malignant group (p<0.001). Tumor size above 10 cms. and postmenopausal status were statistically significant for the malignant ovarian tumor (P<0.001).Bilaterality was significant in malignant compared with benign group (p<0.05). The majority (about 86 %) of malignant tumor was epithelial ovarian cancer, serous cystadenocarcinoma was predominant histologic subtype (40 %case). Most of germ cell tumor was dysgerminoma (67.7%case). Torsion was major complication in both benign and malignant group. Fifty four percent of malignant tumor presented at an early stage.
Conclusion: Postmenopausal women, especially above 50 years, who presented symptoms with abdominal distension, abdominal mass and abnormal vaginal bleeding should be proper bimanual examination and appropriate investigation in the early period to diagnose the disease at an early stage.
Article Details
References
Quaye L, Gayther SA, Ramus SJ, Di Cioccio RA, McGuire V, Hogdall E, et al. The effects of common genetic variants in oncogenes on ovarian cancer survival. Clin Cancer Res 2008;14:5833-9.
Berrino F, De Angelis R, Sant M, Rosso S, Lasota MB, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007;8:773-83.
Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006:60:159-79.
Benjapibal M, Suphanit I, Boribonhiransam D, Vichaidith P, Netphisuth A, Singto N. Primary ovarian tumors in postmenopausal women : a 10 - year review. Siriraj Hosp Gaz 2000; 52:307-12.
Lataifeh I, Marsden DE, Robertson G. Presenting symptoms of epithelial ovarian cancer. Aust N Z J Obstet Gynaecol 2005;45:211-4.
Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 29: 2755-6.
Boyle P, Ferlay J Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-8.
Hani Gabra. FIGO staging for ovarian cancer, ed. D. Keith Edmonds. Obstetrics & Gynecology 7th ed. Blackwell publishing, 2007, pp 625-35. Published online 2008
Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, et al. Ovarian cancer screening in the prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstret Gynecol 2005; 193:1630-9.
Rafiq B, Koiab H, Rao SI. Ovarian Tumors. Professional Med J 2005; 12: 397-403.
Olsen CM, Cnossen J, Green AC, Webb PM. Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors. Eur J Gynaecol Oncol 2007; 28:376-80.
Sultanta A, Hasan S, Siddiqui QA. Ovarian tumors: A five years retrospective study at Abbasi Shahhed Hospital. Karachi Park J Surg 2005; 21: 37-40.
Yawn BP, Barrette BA, Wollan PC. Ovarian cancer: the neglected diagnosis. Mayo Clin Proc 2004; 79: 1277-82.
Ahmed FY, Wiltshaw RP, A’Hern B et al: Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 14:2968, 1996.
Amos Cl, Struewing JP: Genetic epidemiology of epithelial ovarian cancer. Cancer 71: 566, 1993.
Webb PM, Prudie DM, Grover S, Jordan S, Dick MI, Green AC. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol 2004;92:232-9.
William Hamilton. Risk of ovarian cancer in women with symptoms in primary care: population based case control study. BMJ 2009; 339: 6299.
Rufford BD, Jacobs IJ, Mennon บ. Feasibility of screening for ovarian cancer using symptoms as selection criteria. BJOG 2007; 114:59-64
Larry J. Copeland. The adnexal mass and early ovarian cancer. DiSaia. Creasman. Clinical Gynecologic Oncology 7th ed. Elsvier Inc.2007, pp 283-308.
Whittemore AS et al: Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 UScase control study. Am J Epidemiol 136:1184, 1992.
Benjapibal M, Vichaidith P. Primary epithelial ovarian cancer and malignant germ cell tumor of ovary : A review of 368 case. Thai J Obstret Gynecol 2001;13:23-8.
Shaikh NA, Hashmi F, Samoo RP. Pattern of ovarian tumors: report of 15 years experience at Liaqat University Jamshoro. J Liaquat Uni Med Health Sci 2007; 6: 13-5
Gupta N, Bisht D, Agarwal AK, Sharma VK. Retrospective and prospective study f ovarian tumors and tumors like lesions. Indian J Pathol Microbiol 2007; 50: 525-7
Ahmad M, Masood T, Afzal S, Mubarik A. Clinicopathological study of 762 ovarian neoplasms at Army medical college Rawapindi. Pak J Pathol 2004;15: 147-52.
